Polyethylene glycol-modified concanavalin A as an effective agent to stimulate anti-tumor cytotoxicity.
The jack bean lectin, concanavalin A (Con A), was modified with 2,4-bis[O-methoxypoly(ethylene glycol)]-6-chloro-s-triazine, activated PEG2, to form PEG-Con A. The immunoreactivity of PEG-Con A towards anti-Con A antibodies was reduced by increasing the degree of modification of amino groups in the Con A molecule. PEG-Con A had a complete reduction of the immunogenicity in mice and prolonged the clearance-time in blood. Although the mitogenic activity of Con A towards murine spleen cells was reduced by the conjugation with activated PEG2, the administration of PEG-Con A to mice enhanced the anti-tumor cytotoxicity of peripheral lymphocytes against melanoma B16 cells.
Ueno
T
T
Toin Human Science and Technology Center, Department of Biomedical Engineering, Toin University of Yokohama, Japan.
Ohtawa
K
K
Kimoto
Y
Y
Sakurai
K
K
Kodera
Y
Y
Hiroto
M
M
Matsushima
A
A
Nishimura
H
H
Inada
Y
Y
D000818:Animals; D000912:Antibodies, Neoplasm / Q000032:analysis; D003208:Concanavalin A / Q000276:immunology / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006384:Hemagglutination / Q000187:drug effects; D007074:Immunoglobulin G / Q000276:immunology; D008546:Melanoma, Experimental / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008938:Mitosis / Q000187:drug effects; D011092:Polyethylene Glycols / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012997:Solvents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013154:Spleen / Q000473:pathology; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects* / Q000473:pathology; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000912:Antibodies, Neoplasm; D004338:Drug Combinations; D007074:Immunoglobulin G; D012997:Solvents; D003208:Concanavalin A; D011092:Polyethylene Glycols